Navigation Links
Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
Date:9/24/2010

continue following the completion of a chemotherapy course.

Perisurgery: EPOGEN®/PROCRIT® (Epoetin alfa) increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis. (See WARNINGS: Increased Mortality, Serious Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS: Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)

  • ESAs are contraindicated in patients with uncontrolled hypertension.

  • About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit http://www.amgen.com/.

    Forward-Looking StatementsThis news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results o
    '/>"/>

    SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

    Related medicine technology :

    1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
    2. Medarex to Receive Milestone Payment from Amgen
    3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
    4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
    5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
    6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
    7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
    8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
    9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
    10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
    11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
    (Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
    (Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
    Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
    ... June 9 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced new ... mellitus program at,the American Diabetes Association,s 68th ... company,s proprietary recombinant human,hyaluronidase enzyme (rHuPH20) with ...
    ... Pivotal Study Highlighted at Recent Arizona Alzheimer,s ... Consortium Annual Conference in Phoenix -, PHOENIX and ... Health Research Institute today announced that they are,actively enrolling patients ... treatment of Alzheimer,s disease. The study will,evaluate the safety and ...
    Cached Medicine Technology:Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 2Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 3Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 4Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 5Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 2Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 3
    (Date:8/31/2015)... ... September 01, 2015 , ... AthleticTraining.com, provider of CEUs ... hours of new premium on-demand video Evidence Based Practice courses ... before 2014 must complete 50 CEUs before December 31, 2015, which must include ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Jvion, the ... latest predictive use case focused on helping hospital perform under the Center for ... hospital payments are adjusted based on performance across four domains related to care ...
    (Date:8/31/2015)... ... August 31, 2015 , ... ... a wealth of information for specific translation services within the medical and pharmaceutical ... incredible track record of successful work. , ITC Global Translations specializes in professional ...
    (Date:8/31/2015)... ... ... When it comes to undergoing a hair transplant, most patients have donor hair moved from ... to the hair on top of the scalp, as well as filling in areas missing ... hair on other areas of their head. , What about patients who have a limited, ...
    (Date:8/31/2015)... ... 31, 2015 , ... Wound Care Advantage, a leader in ... to Hyperbaric Medicine Course. The next UHMS approved 40-hour Introduction to Hyperbaric Medicine ... Long Beach, CA. The meeting is open for registration from physicians, clinicians and ...
    Breaking Medicine News(10 mins):Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4
    ... Nearly 2.5 million ... Because nearly 90% of eye injuries are preventable with proper protective eyewear, Defog It antifog ... ... Nearly 2.5 million eye injuries occur each year in the United States, with almost half occurring ...
    ... YORK, N.Y. (May 18, 2010) Autism Speaks, the ... major sponsor and scientific participant in the 2010 International ... Society of Autism Research, IMFAR brings together 1800 participants ... who will share their latest research into autism,s causes, ...
    ... Post-surgical improvements on hearing tests greater in those under 65, ... implants provide plenty of benefits for older people with hearing ... well, new research has found. , Dr. David R. ... Milwaukee, examined the medical records of 28 patients aged 65 ...
    ... marketed as Revatio, study finds , TUESDAY, May 18 ... that causes progressive scarring of the lung tissue might ... Viagra, a new study finds. , The disease, called ... thick and stiff, reducing the ability to breathe. There,s ...
    ... generation moves into the ranks of the elderly in the ... to develop will be staggering. Without a current cure, and ... a pressing need for novel solutions to address the multifaceted ... IS FAILING MILLIONSAND HOW WE CAN DO BETTER (Prometheus Books, ...
    ... ... prevalent than ever before. Get the facts on cancer and ways to prevent it from ... ... to educate the nation in the prevention and treatment of cancer. Truecancerfacts.com was written by ...
    Cached Medicine News:Health News:Eye Protection at Home Could Help Prevent 1 Million Home Eye Injures: Tips from Defog It Antifog During National Healthy Vision Month 2010 2Health News:Eye Protection at Home Could Help Prevent 1 Million Home Eye Injures: Tips from Defog It Antifog During National Healthy Vision Month 2010 3Health News:Autism Speaks to play key roles at the 2010 International Meeting for Autism Research 2Health News:Autism Speaks to play key roles at the 2010 International Meeting for Autism Research 3Health News:Younger Is Better When Getting Cochlear Implants 2Health News:Viagra May Aid Those With Lung Fibrosis 2Health News:Viagra May Aid Those With Lung Fibrosis 3Health News:The Alzheimer's solution 2Health News:What Doctors Won't Tell Their Patients About Cancer 2
    ... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
    ... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
    ... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
    Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
    Medicine Products: